Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial.
about
Update on the use of hydroxyurea therapy in sickle cell diseaseIncreased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosisDevelopmental Injury to the Cerebellar Cortex Following Hydroxyurea Treatment in Early Postnatal Life: An Immunohistochemical and Electron Microscopic Study.From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia.Interventions for preventing silent cerebral infarcts in people with sickle cell disease.Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemiaTranslating sickle cell guidelines into practice for primary care providers with Project ECHO.Emerging drugs for sickle cell anemia.Hydroxyurea (hydroxycarbamide) for sickle cell disease.Interventions for chronic kidney disease in people with sickle cell disease.Pediatric sickle cell disease: past successes and future challenges.Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials.A higher prevalence of hematologic malignancies in patients with thalassemia: Background and culprits.The effect of hydroxcarbamide therapy on survival of children with sickle cell disease.Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study.
P2860
Q34737460-EA4B3D02-966C-46E6-BF08-195785291BF8Q35951578-BB0CFEBF-D65C-49A2-BC7B-6301B1AA1287Q36124772-F174FAB8-7247-45ED-9A92-5AD9FB3543B2Q36154109-FA75E7E7-0AC6-464A-B099-570A567D7256Q36370980-3336B971-BC0F-469A-93B3-CA6408503079Q36966277-510A7A5C-0AD8-4D3C-9F32-CC562A4A6597Q37442387-6403F071-8FD3-49B9-8082-E62CDDAA3860Q38272226-A61907B6-81BB-4764-89C5-4113BD2835AAQ38692796-0A43D05E-141D-46D4-A98F-986B52A17B2CQ38696578-BC29D1CC-1138-4374-9240-12E361D35862Q38814652-BAE7BABF-A75A-4368-9B7D-0970C6D9EE9CQ42609605-798A9A48-1F84-4831-B6C0-CA255B3BE550Q48239911-175A94B4-3CCD-4BD5-936B-92D11CB7D851Q51065755-44F8FA2A-F57E-4078-AFDD-24DC049CAC4BQ53757416-4BB18D35-441B-419E-837F-CB96B445C834
P2860
Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Genotoxicity associated with h ...... -HUG Phase III Clinical Trial.
@ast
Genotoxicity associated with h ...... -HUG Phase III Clinical Trial.
@en
type
label
Genotoxicity associated with h ...... -HUG Phase III Clinical Trial.
@ast
Genotoxicity associated with h ...... -HUG Phase III Clinical Trial.
@en
prefLabel
Genotoxicity associated with h ...... -HUG Phase III Clinical Trial.
@ast
Genotoxicity associated with h ...... -HUG Phase III Clinical Trial.
@en
P2093
P2860
P356
P1476
Genotoxicity associated with h ...... -HUG Phase III Clinical Trial.
@en
P2093
Anita S Kulharya
BABY HUG Investigators
Bruce W Thompson
Jonathan M Flanagan
Patrick T McGann
Russell E Ware
Stephen D Dertinger
Thad A Howard
P2860
P304
P356
10.1002/PBC.23365
P577
2011-10-19T00:00:00Z